23 October 2026 September 2026 Quarterly Activity Report and Cash Flow Statement Argent Biopharma Ltd (ASX: RGT) is pleased to update the market for the September 2026 quarter, including material developments up to the date of this report, and attaches its Appendix 4C Quarterly Cash Flow report for...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Story so far
Earlier from Argent Biopharma
- Execution of Loan Facility Agreement
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Appendix 4E and 2026 Annual Report
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- US Veterinary Development Programme for CannEpil Commences
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma